

In the Claims

Claims 31 and 32 have been cancelled.

Claims 1, 6, 8, and 30 are amended as follows.

1. (currently amended) An oral drug delivery composition comprising a chromone wherein (1) not more than 10% of the chromone dissolves after two hours exposure of the composition to simulated gastric fluid and (2) at least 80 ~~15~~% of the chromone dissolves within 5 ~~10~~ minutes of subsequent exposure of the composition to simulated intestinal fluid.

2. (original) A composition according to claim 1 wherein the composition is formulated as a tablet.

3. (original) A composition according to claim 2 wherein the tablet has an enteric coating.

4. (original) A composition according to claim 2 or 3 wherein the composition is still in the form of a tablet at the end of the exposure of the composition to gastric fluid.

5. (original) The composition according to any one of claims 2 to 4 wherein the tablet comprises between about 50mg and 200mg of chromone.

6. (currently amended) A composition according to any one of the preceding claims wherein the composition

further comprises disintegrant at a ratio of at least 1.4:1(w:w) of disintegrant to chromone.

7. (original) A composition according to claim 1 wherein the composition comprises substantially spherical pellets of up to 5 mm diameter comprising the chromone, each pellet having an enteric coating.

8. (currently amended) An oral drug delivery composition comprising a chromone wherein the composition further comprises disintegrant at a ratio of at least 1.5:1 ~~1.4:1~~ (w:w) of disintegrant to chromone.

9. (original) A composition according to claim 6 or claim 8 wherein the ratio of disintegrant to chromone is between about 1.4:1 and 2.5:1

10-15. (previously withdrawn)

16. (previously amended) A composition according to any one of claims 6, 8, or 9 wherein the disintegrant is microcrystalline cellulose.

17-29. (previously withdrawn)

30. (currently amended) A composition according to any one of the preceding claims further comprising an amphoteric surfactant or a surfactant having a hydrophile-lipophile balance (HLB) value of less than about 10.

31-32. (cancelled).

33.. (previously added) A composition according to any one of the preceding claims wherein the chromone is sodium cromoglycate.

Respectfully submitted,

HAUGEN LAW FIRM PLLP

Mark J. Burns, Reg. #46591
Attorney for Applicant
1130 TCF Tower
121 South Eighth Street
Minneapolis, MN 55402
Phone: (612) 339-8300